Rush University Medical Center
Conditions and Treatments
Search by Topic or Doctor's Name
Doctors at Rush Focus on You
At the end of the visit, my goal is to have the patients feel more informed and to feel like their issues have been properly addressed.
— Octavio Vega, MD, internist
I enjoy the challenges of piecing together the puzzle – putting difficult, complicated signs and symptoms together and trying to formulate a diagnosis.
— Patricia Graham, MD, internist
Hear more from doctors at Rush.
Directions and Parking
Health & Wellness
Health News and Advice to Fit Your Life
The choices you make each day can have a huge effect on your health. Rush offers a wealth of resources to help you make good ones.
Maintaining a Healthy WeightTips to help you overcome common barriers to weight maintenance.
Six Signs of Nutrient DeficiencyHair loss, headaches and other signs you may be missing key vitamins and minerals.
About RushHow Medicine Should BeNational Recognition and AccreditationsRush News
Quality and Safety at RushPatient Satisfaction and FeedbackRush in the CommunityDiversity and Inclusion
Disability Rights and AccommodationsCommitment to LGBTQ Health CareVolunteeringBondholder Information
A phase 3 multicenter, randomized, placebo-controlled study to determine the effect of topical SGX301 and fluorescent bulb-light irradiation for the treatment of cutaneous T-cell lymphoma.
A study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis.
A phase 3 multicenter study to evaluate the efficacy and safety of an investigational drug versus vehicle (placebo) in subjects 2 years of age or older with cutaneous common warts.
A clinical study to demonstrate safety and efficacy of E7777 (denileukin diftitox) in persistent or recurrent cutaneous T-cell lymphoma.
A double blind, randomized, vehicle controlled, crossover study to evaluate the safety and efficacy of a topical lotion, for the relief of pruritus in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL).